Tuberculosis costs in Spain and related factors

Gullón-Blanco, José Antonio; Rodríguez-López, Juan; Montes, Manuel-Angel Villanueva; Navascués, Fernando Álvarez; García, José María; Rodrigo, Teresa; Casals, Martí; Caylà, Joan A.; Separ, Grupo de Trabajo Pii-Tb

doi:10.1183/13993003.congress-2016.pa2717

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to death and treatment failure, the higher retreatment rate in the non-adherent group in our study may explain the significant increase in cumulative cost by year. In addition, we found that the non-adherent group spent more inpatient care, which was previously reported ( Gullón-Blanco et al, 2016 ) as the major cost driver. Therefore, TB management to improve patient adherence may reduce the national budget for TB control.…”

Section: Discussionsupporting

confidence: 79%

Real-world association of adherence with outcomes and economic burden in patients with tuberculosis from South Korea claims data

et al. 2022

View full text Add to dashboard Cite

Objectives: We analyzed tuberculosis (TB)-related costs according to treatment adherence, as well as the association between treatment adherence, treatment outcomes, and costs related to drug-susceptible TB in South Korea.Methods: Patients who had newly treated TB in South Korea between 2006 and 2015 were selected from nationwide sample claims data and categorized into adherent and non-adherent groups using the proportion of days TB drugs covered. Patients were followed-up from the initiation of TB treatment. The mean five-year cumulative costs per patient were estimated according to adherence. Moreover, we evaluated the relative ratios to identify cost drivers such as adherence, treatment outcomes, and baseline characteristics using generalized linear models. Four treatment outcomes were included: treatment completion, loss to follow-up, death, and the initiation of multidrug-resistant TB treatment.Results: Out of the 3,799 new patients with TB, 2,662 were adherent, and 1,137 were non-adherent. Five years after initiating TB treatment, the mean TB-related costs were USD 2,270 and USD 2,694 in the adherent and non-adherent groups, respectively. The TB-related monthly cost per patient was also lower in the adherent than in the non-adherent (relative ratio = 0.89, 95% CI 0.92–0.98), while patients who were lost to follow-up spent more on TB-related costs (2.52, 2.24–2.83) compared to those who completed the treatment.Conclusion: Non-adherent patients with TB spend more on treatment costs while they have poorer outcomes compared to adherent patients with TB. Improving patient adherence may lead to effective treatment outcomes and reduce the economic burden of TB. Policymakers and providers should consider commitment programs to improve patient’s adherence.

show abstract

Section: Discussionsupporting

confidence: 79%